ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interatrial shunt (IAS) device did not meet the primary composite efficacy endpoint in a pivotal trial, a result ...

ATLANTA -- An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the RELIEVE-HF trial, though actual harm or benefit seemed to hinge on the patient's ...

An FDA advisory panel gave a unanimous verdict for an interatrial shunt in heart failure: no way. All 15 members of the Circulatory System Devices Panel of the Medical Devices Advisory Committee on ...

There is a persistent lack of effective treatments for heart failure with preserved ejection fraction (HFpEF), so in this study, investigators examined the impact of an atrial shunt among patients ...

BOSTON, MA—Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and elevated left atrial pressures appear to derive lasting benefits from a shunt that diverts ...

BOSTON, MA—This week’s Technology and Heart Failure Therapeutics (THT) 2023 meeting featured more than a dozen talks on interatrial shunts to reduce left atrial pressures and volume overload in heart ...

Results from early clinical evaluation of the Alleviant System to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) was presented today as late-breaking ...

Transcatheter implants designed to alleviate high left atrial (LA) pressures — which, as a possible way to treat heart failure (HF) once seemed like a long shot — are emerging as new stars of heart ...

ATLANTA, GA (May 20, 2022) – Results from early clinical evaluation of the Alleviant System to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) was presented ...